Sanofi and Regeneron amend Kevzara COVID-19 trial

27 April 2020

Partners Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) have announced that – following a review by the Independent Data Monitoring Committee (IDMC) – its research work on Kevzara (sarilumab) in COVID-19 will be scaled back.

The companies have announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating the interleukin-6 receptor antibody in hospitalized patients with severe or critical respiratory illness caused by COVID-19.

"There is an acute need for tailored approaches"In the IDMC’s review of all available Phase II and Phase III data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400mg or placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK